FOR INVESTORS Press releases Choose a page Overview Press Releases Events Financial Info Stock Governance FAQs Year All 2026 2025 2024 2023 2022 2021 2020 2019 2018 2016 2015 2014 November 11, 2026 Nurix Therapeutics Appoints Arati V. Rao, M.D., as Chief Medical Officer November 10, 2026 Nurix Therapeutics to Participate in Upcoming Investor Conferences November 5, 2026 Nurix Therapeutics to Present New and Updated Data from Ongoing Phase 1a/1b Trial of Bexobrutideg (NX-5948) in Relapsed/Refractory CLL/SLL at the 68th ASH Annual Meeting and Exposition November 3, 2026 Nurix Therapeutics Announces Sanofi’s Decision to Discontinue Development of STAT6 Degrader SAR448272 October 12, 2026 Nurix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update October 7, 2026 Nurix Therapeutics Announces First Patient Enrolled in Phase 1b/2 Combination Study of Bexobrutideg in Chronic Lymphocytic Leukemia October 5, 2026 Nurix Therapeutics Announces Second Research Term Extension for Oncology Program Under Collaboration with Gilead Sciences September 29, 2026 Nurix Therapeutics Announces Achievement of $7 Million Milestone Under Strategic Collaboration with Pfizer September 1, 2026 Nurix Therapeutics to Participate in Upcoming September Investor Conferences August 20, 2026 Nurix Therapeutics Announces Appointment of Wes Burwell as Chief Human Resources Officer Print Page Contact IR RSS Email Alerts
Year All 2026 2025 2024 2023 2022 2021 2020 2019 2018 2016 2015 2014 November 11, 2026 Nurix Therapeutics Appoints Arati V. Rao, M.D., as Chief Medical Officer November 10, 2026 Nurix Therapeutics to Participate in Upcoming Investor Conferences November 5, 2026 Nurix Therapeutics to Present New and Updated Data from Ongoing Phase 1a/1b Trial of Bexobrutideg (NX-5948) in Relapsed/Refractory CLL/SLL at the 68th ASH Annual Meeting and Exposition November 3, 2026 Nurix Therapeutics Announces Sanofi’s Decision to Discontinue Development of STAT6 Degrader SAR448272 October 12, 2026 Nurix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update October 7, 2026 Nurix Therapeutics Announces First Patient Enrolled in Phase 1b/2 Combination Study of Bexobrutideg in Chronic Lymphocytic Leukemia October 5, 2026 Nurix Therapeutics Announces Second Research Term Extension for Oncology Program Under Collaboration with Gilead Sciences September 29, 2026 Nurix Therapeutics Announces Achievement of $7 Million Milestone Under Strategic Collaboration with Pfizer September 1, 2026 Nurix Therapeutics to Participate in Upcoming September Investor Conferences August 20, 2026 Nurix Therapeutics Announces Appointment of Wes Burwell as Chief Human Resources Officer
November 5, 2026 Nurix Therapeutics to Present New and Updated Data from Ongoing Phase 1a/1b Trial of Bexobrutideg (NX-5948) in Relapsed/Refractory CLL/SLL at the 68th ASH Annual Meeting and Exposition
November 3, 2026 Nurix Therapeutics Announces Sanofi’s Decision to Discontinue Development of STAT6 Degrader SAR448272
October 12, 2026 Nurix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
October 7, 2026 Nurix Therapeutics Announces First Patient Enrolled in Phase 1b/2 Combination Study of Bexobrutideg in Chronic Lymphocytic Leukemia
October 5, 2026 Nurix Therapeutics Announces Second Research Term Extension for Oncology Program Under Collaboration with Gilead Sciences
September 29, 2026 Nurix Therapeutics Announces Achievement of $7 Million Milestone Under Strategic Collaboration with Pfizer
August 20, 2026 Nurix Therapeutics Announces Appointment of Wes Burwell as Chief Human Resources Officer